Von willebrand disease Market: Epidemiology, Therapies, Companies, DelveInsight | Band Therapeutics, TagCyx Biotechnologies, China Biologic Products, Thrombotargets Corporation, Sanofi

Von willebrand disease emerging therapies, such as WILATE, VONVENDI, VGA039, Efanesoctocog alfa (BIVV001), and others, are expected to boost the Von willebrand disease Market in the upcoming years.

DelveInsight has launched a new report on "Von willebrand disease - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Von willebrand disease, historical and forecasted epidemiology as well as the Von willebrand disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Von willebrand disease market report @ https://www.delveinsight.com/report-store/von-willebrand-disease-vwd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Von willebrand disease Market Report:

The Von Willebrand Disease (VWD) market in the US was valued at over USD 350 million in 2023. The market is expected to grow between 2024 and 2034, driven by rising diagnosed cases and advances in recombinant therapies. Key players in this space include CSL Behring, LFB Biomedicaments SA, Octapharma AG, and Grifols SA.
Market dynamics are likely to evolve due to improved diagnostic methods, increased disease awareness, and higher healthcare spending globally. However, the current treatment pipeline remains mostly in early development stages, with companies like Vega Therapeutics and Sanofi actively working on new therapies.
In December 2023, the US FDA expanded approval for WILATE as the first von Willebrand factor (VWF) concentrate approved for prophylactic use across all VWD types. Additionally, in May 2023, the FDA granted Orphan Drug Designation to VGA039 for treating VWD.
The expanded use of VONVENDI (BAX 111) for both prophylactic and pediatric treatment, especially in the US, is expected to impact the market significantly. Its prior FDA approval in April 2018 for perioperative bleeding management has increased awareness among moderately affected, often undertreated patients with VWF defects.
Recent cryo-electron microscopy studies of the BIVV001 complex have detailed the molecular interaction between factor VIII (FVIII) and VWF, which is essential for blood clotting after vascular injury. Mutations in the VWF D′D3 domains that impair FVIII binding cause VWD type 2N.
In 2023, there were about 13,000 diagnosed cases of Von Willebrand Disease in the US, with numbers projected to rise throughout the 2020-2034 period. Females represent the majority, accounting for approximately 55% of these cases, totaling over 7,000 in 2023.
In January 2025, Star Therapeutics, a clinical-stage biotech firm specializing in advanced antibody development, announced that the FDA has awarded Fast Track designation to VGA039 for treating von Willebrand disease (VWD).
In January 2025, Star Therapeutics' investigational monoclonal antibody, VGA039, targeting Protein S, was granted Fast Track designation by the FDA for the treatment of VWD. VGA039 is potentially the first subcutaneous therapy addressing all types of VWD, offering a convenient dosing regimen .
Key Von willebrand disease companies such as Band Therapeutics, TagCyx Biotechnologies, China Biologic Products, Thrombotargets Corporation, Sanofi, and others are evaluating new drugs for Von willebrand disease to improve the treatment landscape.
Promising Von willebrand disease therapies include WILATE, VONVENDI, VGA039, Efanesoctocog alfa (BIVV001), and others.

Von willebrand disease Overview

Von Willebrand disease is a genetic disorder caused by a deficiency or dysfunction of von Willebrand factor (VWF), a protein essential for blood clotting. VWF helps bind factor VIII and platelets to blood vessel walls, forming a platelet plug during clotting. The disease is diverse and is generally classified into inherited and acquired types.

Diagnosis involves multiple blood tests, including measuring VWF antigen levels, clotting time, clot formation ability, and platelet function.

The Von Willebrand Disease market report covers the disease's pathophysiology, diagnostic methods, and treatment strategies, along with a real-world overview of a patient's journey from initial symptoms through diagnosis and treatment.

Von willebrand disease Market Outlook

The current therapeutic landscape for Von Willebrand Disease (VWD) in the United States is categorized into three primary treatment classes. Non-replacement therapy involves the use of desmopressin (DDAVP), which increases plasma levels of von Willebrand factor (VWF) and is typically used for milder cases. Replacement therapy relies on plasma-derived coagulation factor concentrates such as HUMATE-P (CSL Behring), ALPHANATE (Grifols), IMMUNATE, and WILATE (Octapharma) to replace deficient VWF directly. Adjunct therapy includes antifibrinolytic agents like tranexamic acid (CYCLOKAPRON), which help control bleeding by preventing clot breakdown.

A newer addition to the replacement therapy segment is VONVENDI, a recombinant VWF concentrate that offers an alternative to plasma-derived options. For more severe cases, especially in Type 2 and Type 3 VWD or during significant bleeding episodes, virally inactivated factor VIII concentrates containing VWF have emerged as a more optimal second-line treatment. These options help manage bleeding more effectively when first-line therapies are insufficient.

Several companies, including Sanofi, Octapharma, Vega Therapeutics, and others, are actively pursuing the development of novel treatments for VWD. Their investigational therapies, currently in various stages of clinical development, aim to improve efficacy, safety, and convenience for patients, potentially transforming the treatment landscape over the coming years.

Discover how the Von willebrand disease market is rising in the coming years @ https://www.delveinsight.com/sample-request/von-willebrand-disease-vwd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Von willebrand disease Marketed Drugs
WILATE: OctaPharma
VONVENDI: Takeda Pharmaceuticals

Von willebrand disease Emerging Drugs
VGA039: Vega Therapeutics
Efanesoctocog alfa (BIVV001): Sanofi

Scope of the Von willebrand disease Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Von willebrand disease Companies: Band Therapeutics, TagCyx Biotechnologies, China Biologic Products, Thrombotargets Corporation, Sanofi, and others
Key Von willebrand disease Therapies: WILATE, VONVENDI, VGA039, Efanesoctocog alfa (BIVV001), and others
Von willebrand disease Therapeutic Assessment: Von willebrand disease current marketed and Von willebrand disease emerging therapies
Von willebrand disease Market Dynamics: Von willebrand disease market drivers and Von willebrand disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Von willebrand disease Unmet Needs, KOL's views, Analyst's views, Von willebrand disease Market Access and Reimbursement

To know what's more in our Von willebrand disease report, visit https://www.delveinsight.com/report-store/von-willebrand-disease-vwd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Von willebrand disease Market Report:
Von willebrand disease market report covers a descriptive overview and comprehensive insight of the Von willebrand disease Epidemiology and Von willebrand disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Von willebrand disease market report provides insights into the current and emerging therapies.
The Von willebrand disease market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Von willebrand disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Von willebrand disease market.

Got queries? Click here to know more about the Von willebrand disease market Landscape https://www.delveinsight.com/sample-request/von-willebrand-disease-vwd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Von willebrand disease Patient Share (%) Overview at a Glance
5. Von willebrand disease Market Overview at a Glance
6. Von willebrand disease Disease Background and Overview
7. Von willebrand disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Von willebrand disease
9. Von willebrand disease Current Treatment and Medical Practices
10. Unmet Needs
11. Von willebrand disease Emerging Therapies
12. Von willebrand disease Market Outlook
13. Country-Wise Von willebrand disease Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Von willebrand disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Von willebrand disease Market Outlook 2034 https://www.delveinsight.com/report-store/von-willebrand-disease-vwd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Von willebrand disease Pipeline Insights, DelveInsight

"Von willebrand disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Von willebrand disease market. A detailed picture of the Von willebrand disease pipeline landscape is provided, which includes the disease overview and Von willebrand disease treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.